Blood test guided use of AstraZeneca drug shows major breakthrough in breast cancer treatment

Jun 1, 2025

Breast cancer treatment India, AstraZeneca breast drug, Cancer drug resistance, Imfinzi stomach cancer
Breast cancer treatment India, AstraZeneca breast drug, Cancer drug resistance, Imfinzi stomach cancer

Source: Reuters

Share:

At the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers unveiled promising results showing that AstraZeneca’s experimental pill camizestrant guided by a liquid biopsy blood test can significantly delay breast cancer progression in women with early signs of drug resistance.

Key highlights

New data from ASCO meeting

  • First trial to use liquid biopsy to detect ESR1 gene mutations and guide early treatment switch.

  • Camizestrant delayed disease progression by 16 months vs 9.2 months with standard therapy.

  • Shows 56% reduction in risk of disease progression or death in hormone receptor-positive, HER2-negative breast cancer.

Game changing early intervention approach

  • Switching treatments based on blood test results before tumors show on scans could redefine clinical practice.

  • Experts say this "early switch" could help doctors stay ahead of drug resistance and avoid delays in care.

Safe profile with no new side effects

  • Trial included 315 women identified via blood tests.

  • No major dropouts or new adverse effects observed.

Global impact and regulatory future

  • Drug not yet FDA approved, but findings expected to push regulatory pathways forward.

  • AstraZeneca CEO called the approach “the future of cancer treatment,” acknowledging initial challenges but long-term adoption potential.

Additional results from Imfinzi trial

  • AstraZeneca's Imfinzi (durvalumab) with FLOT chemotherapy reduced cancer recurrence or progression by 29% in early-stage stomach and esophageal cancers.

  • Both landmark studies were published in the New England Journal of Medicine.

This dual breakthrough camizestrant in breast cancer and Imfinzi in stomach cancer marks a significant advancement in personalized cancer care. Liquid biopsy-guided treatment and immunotherapy combinations could reshape cancer management globally, offering earlier, more precise interventions for patients.

Breast cancer treatment India
AstraZeneca breast drug
Cancer drug resistance
Imfinzi stomach cancer
Breast cancer treatment India
AstraZeneca breast drug
Cancer drug resistance
Imfinzi stomach cancer

Blood test guided use of AstraZeneca drug shows major breakthrough in breast cancer treatment

Jun 1, 2025

Breast cancer treatment India, AstraZeneca breast drug, Cancer drug resistance, Imfinzi stomach cancer
Breast cancer treatment India, AstraZeneca breast drug, Cancer drug resistance, Imfinzi stomach cancer

Source: Reuters

At the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers unveiled promising results showing that AstraZeneca’s experimental pill camizestrant guided by a liquid biopsy blood test can significantly delay breast cancer progression in women with early signs of drug resistance.

Key highlights

New data from ASCO meeting

  • First trial to use liquid biopsy to detect ESR1 gene mutations and guide early treatment switch.

  • Camizestrant delayed disease progression by 16 months vs 9.2 months with standard therapy.

  • Shows 56% reduction in risk of disease progression or death in hormone receptor-positive, HER2-negative breast cancer.

Game changing early intervention approach

  • Switching treatments based on blood test results before tumors show on scans could redefine clinical practice.

  • Experts say this "early switch" could help doctors stay ahead of drug resistance and avoid delays in care.

Safe profile with no new side effects

  • Trial included 315 women identified via blood tests.

  • No major dropouts or new adverse effects observed.

Global impact and regulatory future

  • Drug not yet FDA approved, but findings expected to push regulatory pathways forward.

  • AstraZeneca CEO called the approach “the future of cancer treatment,” acknowledging initial challenges but long-term adoption potential.

Additional results from Imfinzi trial

  • AstraZeneca's Imfinzi (durvalumab) with FLOT chemotherapy reduced cancer recurrence or progression by 29% in early-stage stomach and esophageal cancers.

  • Both landmark studies were published in the New England Journal of Medicine.

This dual breakthrough camizestrant in breast cancer and Imfinzi in stomach cancer marks a significant advancement in personalized cancer care. Liquid biopsy-guided treatment and immunotherapy combinations could reshape cancer management globally, offering earlier, more precise interventions for patients.

Share:

Breast cancer treatment India
AstraZeneca breast drug
Cancer drug resistance
Imfinzi stomach cancer
Breast cancer treatment India
AstraZeneca breast drug
Cancer drug resistance
Imfinzi stomach cancer